James Bluett

1.9k total citations
32 papers, 415 citations indexed

About

James Bluett is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, James Bluett has authored 32 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Rheumatology, 11 papers in Genetics and 7 papers in Pathology and Forensic Medicine. Recurrent topics in James Bluett's work include Rheumatoid Arthritis Research and Therapies (20 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). James Bluett is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). James Bluett collaborates with scholars based in United Kingdom, Ireland and Albania. James Bluett's co-authors include Anne Barton, Suzanne Verstappen, Kimme L Hyrich, Lis Cordingley, Katherine A. Hollywood, Yun Xu, Abdu Subaihi, Drupad K. Trivedi, Howbeer Muhamadali and David I. Ellis and has published in prestigious journals such as The Lancet, Analytical Chemistry and Annals of the Rheumatic Diseases.

In The Last Decade

James Bluett

29 papers receiving 410 citations

Peers

Countries citing papers authored by James Bluett

Since Specialization

Citations

This map shows the geographic impact of James Bluett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Bluett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Bluett more than expected).

Fields of papers citing papers by James Bluett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Bluett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Bluett. The network helps show where James Bluett may publish in the future.

Co-authorship network of co-authors of James Bluett

This figure shows the co-authorship network connecting the top 25 collaborators of James Bluett. A scholar is included among the top collaborators of James Bluett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Bluett. James Bluett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update 2025 ·Basic & Clinical Pharmacology & Toxicology ·James Bluett, (unknown), (unknown), Floris C. Loeff, Mehmet İtik, David Ternant, Céline Desvignes, Denis Mulleman, Silje Skrede	0
2	Therapeutic drug monitoring education: The current state 2025 ·British Journal of Clinical Pharmacology ·Guenka Petrova, (unknown), Konstantin Tachkov, Marlene Santos, James Bluett, (unknown), (unknown), (unknown), (unknown), Mehtap Çakmak Barsbay, Denis Mulleman	0
3	Towards Personalized Medicine in Rheumatoid Arthritis 2024 ·Open Access Rheumatology Research and Reviews ·(unknown), James Bluett	9
4	Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis 2024 ·Pharmaceutics ·Stephanie F Ling, Kayode Ogungbenro, Adam S. Darwich, (unknown), Nisha Nair, James Bluett, Ann W Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L Hyrich, Anne Barton, Darren Plant	0
5	Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA 2024 ·Lara D. Veeken ·Man Fung Tsoi, Lianne Kearsley‐Fleet, (unknown), Kath Watson, Kimme L Hyrich, James Bluett, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
6	A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures 2023 ·Lara D. Veeken ·Stephanie F Ling, (unknown), Nisha Nair, James Bluett, Ann W Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L Hyrich, Anne Barton, Darren Plant	2
7	Development of a sensitive biochemical assay for the detection of tofacitinib adherence 2023 ·Analytical Methods ·Stephanie J. Church, Kimme L Hyrich, Kayode Ogungbenro, Richard D. Unwin, Anne Barton, James Bluett	2
8	P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial 2023 ·Lara D. Veeken ·James Bluett, Kimme L Hyrich, Brian Keevil, Patty Doran, Anne Barton	1
9	Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis? 2022 ·The Pharmacogenomics Journal ·(unknown), Andrew P. Morris, Anne Barton, James Bluett	7
10	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) 2022 ·BMJ Open ·Abhishek Abhishek, (unknown), Áine McKnight, Laura C. Coates, James Bluett, Vicki S Barber, Lucy Cureton, Anne Francis, D. E. Appelbe, (unknown), Patrick Julier, Nicholas Peckham, Ana M. Valdes, Ines Rombach, Daniel M. Altmann, Jonathan S Nguyen-Van-Tam, Hywel C Williams, Jonathan Cook	1
11	Pharmacogenetics of Tnf Inhibitor⟒esponse in Rheumatoid Arthritis Utilizing the Two-Component Disease Activity Score 2020 ·Pharmacogenomics ·(unknown), Nisha Nair, Darren Plant, Kimme L Hyrich, Ann W Morgan, Andrew P. Morris, Anthony G. Wilson, John D. Isaacs, Anne Barton, James Bluett, (unknown)	3
12	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate 2020 ·Lara D. Veeken ·Anne Barton, Meghna Jani, Christine Bundy, James Bluett, Stephen McDonald, Brian Keevil, (unknown), (unknown), Ian N Bruce, Pauline Ho, Eoghan McCarthy, (unknown), Ben Parker, Kimme L Hyrich, Rachel Gorodkin	5
13	Development and validation of a methotrexate adherence assay 2019 ·Annals of the Rheumatic Diseases ·James Bluett, Isabel Riba‐Garcia, Suzanne Verstappen, (unknown), Kayode Ogungbenro, Richard D. Unwin, Anne Barton	17
14	Quantitative Online Liquid Chromatography–Surface-Enhanced Raman Scattering (LC-SERS) of Methotrexate and its Major Metabolites 2017 ·Analytical Chemistry ·Abdu Subaihi, Drupad K. Trivedi, Katherine A. Hollywood, James Bluett, Yun Xu, Howbeer Muhamadali, David I. Ellis, Royston Goodacre	78
15	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis 2017 ·Rheumatology and Therapy ·James Bluett, Meghna Jani, Deborah Symmons	14
16	Precision Medicine in Rheumatoid Arthritis 2017 ·Rheumatic Disease Clinics of North America ·James Bluett, Anne Barton	31
17	A HPLC-SRM-MS based method for the detection of adherence to low-dose oral methotrexate 2015 ·Arthritis & Rheumatism ·James Bluett, (unknown), Kayode Ogungbenro, Isabel Riba‐Garcia, Richard D. Unwin, Suzanne Verstappen, Anne Barton	1
18	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort 2013 ·The Pharmacogenomics Journal ·(unknown), James Bluett, (unknown), Darren Plant, Kimme L Hyrich, Ann W Morgan, Anthony G. Wilson, John D. Isaacs, Anne Barton	4
19	Cervical Spine Calcinosis in Systemic Sclerosis 2013 ·The Journal of Rheumatology ·James Bluett, (unknown), (unknown), Ariane L. Herrick	11
20	What Have Genome-Wide Studies Told Us About Psoriatic Arthritis? 2012 ·Current Rheumatology Reports ·James Bluett, Anne Barton	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact